Ovid Therapeutics Inc 2026年季度报告

FORM 10-Q_______________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March31, 2026OR Ovid Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter)_______________________________________________________ Registrant’s telephone number, including area code: (646) 661-7661 Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, par value $0.001 per shareOVIDThe Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None_______________________________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to the filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act.: Large Accelerated FilerNon-accelerated FilerEmerging growth company Accelerated FilerSmaller Reporting Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) YesNoAs of May8, 2026, the registrant had 186,640,102 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Comprehensive Loss5Condensed Consolidated Statements of Stockholders’ Equity6Condensed Consolidated Statements of Cash Flows7Notes to Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item 3.Quantitative and Qualitative Disclosures About Market Risk33Item 4.Controls and Procedures33PART II.OTHER INFORMATIONItem 1.Legal Proceedings34Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds68Item 5.Other Information68Item 6.Exhibits69Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or theExchange Act. All statements other than statements of historical fact are “forward-looking statements” for purposes of this QuarterlyReport on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,”“assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”“plan,” “positioned,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative or plural of those terms, andsimilar expressions. Forward-looking statements include, but are not limited to, statements about: •our ability to identify additional novel compounds with significant commercial potential to acquire or in-license;•our ability to successfully acquire or in-license additional drug candidates on reasonable terms;•the potential use, development and therapeutic potential of the drug candidates in our pipeline;•our ability to develop medical therapies that deliver preferable safety and tolerability profiles relative to approveddrugs;•our estimates regarding expenses, future revenue including any royalty or milestone payments, capital requirementsand needs for additional financing;•our ability to obtain regulatory approval of our current and future drug candidates;•our expectations regarding the timing of initiation, completion, and results and data from clinical trials and potentialregulatory filings;•our expectations regarding the potential market size for drug candidates and the rate and degree of marketacceptance of such drug candidates;•our ability to fund our working